ArticleScience China. Life sciences2022
Long-term clinical observation of patients with acute and chronic complete spinal cord injury after transplantation of NeuroRegen scaffold.
Article in Science China. Life sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 4 syntheses or guidelines pooled it, 57 citations in OpenAlex.
- Pooled it
- The Efficacy of Different Material Scaffold-Guided Cell Transplantation in the Treatment of Spinal Cord Injury in Rats: A Systematic Review and Network Meta-analysis.Cellular and molecular neurobiology · 2024Pooled it
- Clinical translation of stem cell therapy for spinal cord injury still premature: results from a single-arm meta-analysis based on 62 clinical trials.BMC medicine · 2022Pooled it
- Comparing the Efficacy and Safety of Cell Transplantation for Spinal Cord Injury: A Systematic Review and Bayesian Network Meta-Analysis.Frontiers in cellular neuroscience · 2022Pooled it
- Effect of autologous bone marrow stem cells-scaffold transplantation on the ongoing pregnancy rate in intrauterine adhesion women: a randomized, controlled trial.Science China. Life sciences · 2024Trial
- Tissue engineering for traumatic spinal cord injury: Research advances and clinical translation.Bioactive materials · 2026Review
- Animal models of spinal cord injury in neuro-urological research.Nature reviews. Urology · 2026Review
- Research on GM1 bound bMSCs loaded with SF hydrogel for spinal cord injury repair.Journal of translational medicine · 2026Article
- Mechanisms and Applications of Conductive Biomaterials in Spinal Cord Injury Repair.Biomaterials research · 2026Review
- Engineering neural recovery: Micro/nano-structured materials for nerve regeneration.Materials today. Bio · 2025Review
- Biomaterial scaffold stiffness influences the foreign body reaction, tissue stiffness, angiogenesis and neuroregeneration in spinal cord injury.Bioactive materials · 2025Article
- Insights into Astrogliosis, Inflammation Processes, and Emerging Treatments by Exosome Therapy and Low-Level Laser Therapy for Spinal Cord Injury: A Systematic Review.Journal of lasers in medical sciences · 2025Review
- Preclinical evaluation of aligned fibrin nanofibre hydrogels in a non-human primate model of spinal cord injury: A pilot study.Biomaterials translational · 2025Article
- Exosome-Loaded Bioscaffolds for Spinal Cord Injuries: A Review.Stem cells international · 2025Review
- Injectable alginate chitosan hydrogel as a promising bioengineered therapy for acute spinal cord injury.Scientific reports · 2024Article
- Promotion of nerve regeneration and motor function recovery in SCI rats using LOCAS-iPSCs-NSCs.Stem cell research & therapy · 2024Article
- Functional biomaterials for modulating the dysfunctional pathological microenvironment of spinal cord injury.Bioactive materials · 2024Review
- Effect of Electroacupuncture Stimulation on Proliferation and Differentiation of Endogenous Neural Stem Cells in Rats with Spinal Cord Injury.Molecular neurobiology · 2024Article
- Regional biomechanical characterization of the spinal cord tissue: dynamic mechanical response.Frontiers in bioengineering and biotechnology · 2024Article
- An Insight into the Prospects and Drawbacks of Stem Cell Therapy for Spinal Cord Injuries: Ongoing Trials and Future Directions.Brain sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Spinal cord injury (SCI) often results in an inhibitory environment at the injury site. In our previous studies, transplantation of a scaffold combined with stem cells was proven to induce neural regeneration in animal models of complete SCI. Based on these preclinical studies, collagen scaffolds loaded with the patients' own bone marrow mononuclear cells or human umbilical cord mesenchymal stem cells were transplanted into SCI patients. Fifteen patients with acute complete SCI and 51 patients with chronic complete SCI were enrolled and followed up for 2 to 5 years. No serious adverse events related to functional scaffold transplantation were observed. Among the patients with acute SCI, five patients achieved expansion of their sensory positions and six patients recovered sensation in the bowel or bladder. Additionally, four patients regained voluntary walking ability accompanied by reconnection of neural signal transduction. Among patients with chronic SCI, 16 patients achieved expansion of their sensation level and 30 patients experienced enhanced reflexive defecation sensation or increased skin sweating below the injury site. Nearly half of the patients with chronic cervical SCI developed enhanced finger activity. These long-term follow-up results suggest that functional scaffold transplantation may represent a feasible treatment for patients with complete SCI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.